New treatment methods for acute myeloid leukemia using targeted radiation therapy
Novel Approaches to CD33-Directed Radioimmunotherapy
['FUNDING_R37'] · FRED HUTCHINSON CANCER CENTER · NIH-10977966
This study is looking at a new way to treat acute myeloid leukemia (AML) using a special type of radiation that targets leukemia cells, which could make treatments safer and more effective for patients like you.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10977966 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative therapies for acute myeloid leukemia (AML) by using targeted radiation delivered through antibodies that specifically bind to CD33, a protein found on leukemia cells. The study aims to improve upon existing treatments by utilizing astatine-211, a radioactive substance with a shorter half-life and fewer harmful byproducts compared to previous options. By testing these new therapies in humanized mice, the researchers hope to enhance the effectiveness and safety of CD33-directed radioimmunotherapy, potentially leading to better outcomes for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who express the CD33 protein on their leukemia cells.
Not a fit: Patients with acute myeloid leukemia who do not express CD33 or have other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promise with antibody-drug conjugates targeting CD33, but this approach using astatine-211 represents a novel strategy that has not been extensively tested.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WALTER, ROLAND BRUNO — FRED HUTCHINSON CANCER CENTER
- Study coordinator: WALTER, ROLAND BRUNO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.